WO2001087335A3 - Method for selectively inhibiting ghrelin action - Google Patents

Method for selectively inhibiting ghrelin action Download PDF

Info

Publication number
WO2001087335A3
WO2001087335A3 PCT/US2001/011752 US0111752W WO0187335A3 WO 2001087335 A3 WO2001087335 A3 WO 2001087335A3 US 0111752 W US0111752 W US 0111752W WO 0187335 A3 WO0187335 A3 WO 0187335A3
Authority
WO
WIPO (PCT)
Prior art keywords
selectively inhibiting
ghrelin
comprises administering
inhibiting ghrelin
ghrelin action
Prior art date
Application number
PCT/US2001/011752
Other languages
French (fr)
Other versions
WO2001087335A2 (en
Inventor
Henry Uhlman Bryant
Mark Louis Heiman
Original Assignee
Lilly Co Eli
Henry Uhlman Bryant
Mark Louis Heiman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Henry Uhlman Bryant, Mark Louis Heiman filed Critical Lilly Co Eli
Priority to US10/258,259 priority Critical patent/US20030211967A1/en
Priority to AU2001259056A priority patent/AU2001259056A1/en
Priority to EP01932539A priority patent/EP1286697A2/en
Publication of WO2001087335A2 publication Critical patent/WO2001087335A2/en
Publication of WO2001087335A3 publication Critical patent/WO2001087335A3/en
Priority to US11/106,899 priority patent/US20050201938A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

The present invention provides a method selectively inhibiting ghrelin activity to treat a variety of diseases including obesity and related disorders, particularly in individuals who are genetically predisposed. One aspect of the invention comprises administering an agent that effectively neutralizes ghrelin. Another aspect comprises administering a ghrelin receptor (growth hormone secretagogue receptor) antagonist.
PCT/US2001/011752 2000-05-17 2001-05-07 Method for selectively inhibiting ghrelin action WO2001087335A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/258,259 US20030211967A1 (en) 2001-05-07 2001-05-07 Method for selectively inhibiting ghrelin action
AU2001259056A AU2001259056A1 (en) 2000-05-17 2001-05-07 Method for selectively inhibiting ghrelin action
EP01932539A EP1286697A2 (en) 2000-05-17 2001-05-07 Method for selectively inhibiting ghrelin action
US11/106,899 US20050201938A1 (en) 2000-05-17 2005-04-15 Method for selectively inhibiting ghrelin action

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20489700P 2000-05-17 2000-05-17
US60/204,897 2000-05-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/106,899 Continuation US20050201938A1 (en) 2000-05-17 2005-04-15 Method for selectively inhibiting ghrelin action

Publications (2)

Publication Number Publication Date
WO2001087335A2 WO2001087335A2 (en) 2001-11-22
WO2001087335A3 true WO2001087335A3 (en) 2002-05-16

Family

ID=22759933

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/011752 WO2001087335A2 (en) 2000-05-17 2001-05-07 Method for selectively inhibiting ghrelin action

Country Status (3)

Country Link
EP (1) EP1286697A2 (en)
AU (1) AU2001259056A1 (en)
WO (1) WO2001087335A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906618B2 (en) 2000-02-18 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for parallel processing of micro-volume liquid reactions
US9266108B2 (en) 2004-03-12 2016-02-23 Life Technologies Corporation Nanoliter array loading
US9428800B2 (en) 2002-12-20 2016-08-30 Life Technologies Corporation Thermal cycling apparatus and method

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1330306A2 (en) 2000-10-10 2003-07-30 BioTrove, Inc. Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
US20100261159A1 (en) 2000-10-10 2010-10-14 Robert Hess Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
WO2002060472A1 (en) * 2001-01-31 2002-08-08 Chugai Seiyaku Kabushiki Kaisha Remedies for hyponutrition status
CA2446857A1 (en) * 2001-05-10 2002-11-14 Queensland University Of Technology Reproductive cancer diagnosis and therapy
EP2050460A1 (en) 2001-09-24 2009-04-22 Imperial Innovations Limited PYY and agonists thereof for modification of feeding behaviour
US7666833B2 (en) 2001-12-18 2010-02-23 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
ATE552031T1 (en) 2001-12-18 2012-04-15 Alize Pharma Sas PHARMACEUTICAL COMPOSITIONS CONTAINING NON-ACYLATED GHRELIN FOR THE TREATMENT OF INSULIN RESISTANCE
IL162796A0 (en) 2002-05-21 2005-11-20 Kenji Kangawa Medicinal compositions containing ghrelin
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US20060276381A1 (en) * 2002-07-05 2006-12-07 Chugai Seiyaki Kabushiki Kaisha Remedy for diabetes
AU2003251681A1 (en) 2002-08-01 2004-02-23 Noxxon Pharma Ag Ghrelin binding nucleic acids
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
JP2006504413A (en) * 2002-09-12 2006-02-09 ファーメクサ エイ／エス Immunization against autologous ghrelin
AU2003291967A1 (en) * 2002-12-20 2004-07-14 7Tm Pharma A/S Ghrelin receptor inverse agonist for regulation of feeding behaviours
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004084943A1 (en) * 2003-03-19 2004-10-07 Beth Israel Deaconess Medical Center, Inc Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
EP1670827A2 (en) * 2003-09-05 2006-06-21 Eli Lilly And Company Anti-ghrelin antibodies
US7825090B2 (en) 2003-10-24 2010-11-02 Alizé Pharma SAS Use of ghrelin and unacylated ghrelin compositions for treating insulin resistance
US7282050B2 (en) 2003-10-31 2007-10-16 Medtronic, Inc. Ablation of exterior of stomach to treat obesity
US7252665B2 (en) 2003-10-31 2007-08-07 Medtronic, Inc Ablation of stomach lining to reduce stomach acid secretion
EA009376B1 (en) * 2003-11-10 2007-12-28 Нокссон Фарма Аг Nucleic acids specifically binding bioactive ghrelin
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
WO2005097831A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of isolated binding members capable of binding specifically to secretagogues
WO2005097830A2 (en) * 2004-04-07 2005-10-20 Aditech Pharma Ab Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds
WO2005112903A2 (en) * 2004-05-14 2005-12-01 Novo Nordisk A/S Use of ghrelin antagonists for improving cognition and memory
GB0411014D0 (en) * 2004-05-18 2004-06-23 Haptogen Ltd Methods for the control treatment and management of obesity
CA2569235A1 (en) * 2004-07-14 2006-02-23 Eli Lilly And Company Anti-ghrelin antibodies
US20060105453A1 (en) 2004-09-09 2006-05-18 Brenan Colin J Coating process for microfluidic sample arrays
EP2286838A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related disorders
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
EP1856154A1 (en) 2005-02-23 2007-11-21 Eli Lilly And Company Humanized anti-ghrelin antibodies
AR052741A1 (en) 2005-04-08 2007-03-28 Noxxon Pharma Ag NUCLEIC ACIDS FROM UNION TO GHRELIN
US7736392B2 (en) 2005-04-28 2010-06-15 Medtronic, Inc. Bulking of upper esophageal sphincter for treatment of obesity
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
BRPI0614649A2 (en) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc hybrid polypeptides with selectable properties
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US8992928B2 (en) 2006-02-11 2015-03-31 Victor Raso Isolated monoclonal antibody or antigen-binding fragment that cleaves octanoylated native ghrelin
US20110143992A1 (en) * 2006-02-13 2011-06-16 Dennis Taub Methods and Compositions Related to GHS-R Antagonists
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
MX2009012969A (en) 2007-05-31 2010-04-27 Alize Pharma Sas Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders.
US8318664B2 (en) 2007-05-31 2012-11-27 Alize Pharma Sas Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2714617A1 (en) 2008-03-06 2009-09-11 Banyu Pharmaceutical Co., Ltd. Alkylaminopyridine derivative
ES2522968T3 (en) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8476408B2 (en) 2008-06-13 2013-07-02 Alize Pharma Sas Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
ES2624828T3 (en) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
MX2011004551A (en) 2008-10-30 2011-05-25 Merck Sharp & Dohme Isonicotinamide orexin receptor antagonists.
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
JP2013509434A (en) 2009-10-30 2013-03-14 トランザイム・ファーマ，インコーポレイテッド Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of use thereof
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA025380B1 (en) 2011-02-25 2016-12-30 Мерк Шарп Энд Домэ Корп. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
AR088352A1 (en) 2011-10-19 2014-05-28 Merck Sharp & Dohme ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
LT2790721T (en) 2011-12-15 2019-02-11 Millendo Therapeutics Sas Fragments of unacylated ghrelin for use in the treatment of prader-willi syndrome
KR20150036245A (en) 2012-08-02 2015-04-07 머크 샤프 앤드 돔 코포레이션 Antidiabetic tricyclic compounds
RU2015140066A (en) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. ANTI-DIABETIC BICYCLIC COMPOUNDS
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (en) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド Ultra high purity agonist of guanylate cyclase C, method for producing and using the same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2926685A1 (en) 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
CN113121450A (en) 2014-08-29 2021-07-16 Tes制药有限责任公司 Alpha-amino-beta-carboxymuconate semialdehyde decarboxylase inhibitors
BR112019007543A2 (en) 2016-10-14 2019-07-02 Tes Pharma S R L alpha-amino-beta-carboximuconic acid inhibitors semialdehyde decarboxylase
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
AR117122A1 (en) 2018-11-20 2021-07-14 Tes Pharma S R L A-AMINO-b-CARBOXIMUCONIC ACID INHIBITORS SEMIALDEHYDE DECARBOXYLASE
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
AU2021329805B2 (en) 2020-08-18 2024-02-29 Merck Sharp & Dohme Llc Bicycloheptane pyrrolidine orexin receptor agonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021730A1 (en) * 1995-12-13 1997-06-19 Merck & Co., Inc. Growth hormone secretagogue receptor family
WO2000002919A1 (en) * 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
WO2000009538A2 (en) * 1998-08-10 2000-02-24 Merck & Co., Inc. Canine growth hormone secretagogue receptor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021730A1 (en) * 1995-12-13 1997-06-19 Merck & Co., Inc. Growth hormone secretagogue receptor family
WO2000002919A1 (en) * 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
WO2000009538A2 (en) * 1998-08-10 2000-02-24 Merck & Co., Inc. Canine growth hormone secretagogue receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOJIMA MASAYASU ET AL: "Ghrelin is a growth-hormone-releasing acylated peptide from stomach.", NATURE (LONDON), vol. 402, no. 6762, 9 December 1999 (1999-12-09), pages 656 - 660, XP002187791, ISSN: 0028-0836 *
SMITH R G ET AL: "A nonpeptidyl growth hormone secretagogue.", SCIENCE, (1993 JUN 11) 260 (5114) 1640-3., XP002187790 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906618B2 (en) 2000-02-18 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for parallel processing of micro-volume liquid reactions
US9518299B2 (en) 2000-02-18 2016-12-13 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for parallel processing of micro-volume liquid reactions
US9428800B2 (en) 2002-12-20 2016-08-30 Life Technologies Corporation Thermal cycling apparatus and method
US9266108B2 (en) 2004-03-12 2016-02-23 Life Technologies Corporation Nanoliter array loading

Also Published As

Publication number Publication date
EP1286697A2 (en) 2003-03-05
WO2001087335A2 (en) 2001-11-22
AU2001259056A1 (en) 2001-11-26

Similar Documents

Publication Publication Date Title
WO2001087335A3 (en) Method for selectively inhibiting ghrelin action
MXPA01009544A (en) Method for treating and/or preventing retinal diseases with sustained release corticosteroids.
EP1427377A4 (en) Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate specific membrane antigen
WO2003018516A3 (en) Glucagon-like peptide-1 analogs
WO2004006853A3 (en) Treatment and prophylaxis with 4-1bb-binding agents
WO2001079460A3 (en) Polypeptides having haloperoxidase activity
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
HUP0303976A3 (en) Combination therapy using anti-egfr antibodies and hormone antagonists
WO2003057837A3 (en) Methods for using anti-muc18 antibodies
CY2567B1 (en) Treatment of normotensive glaucoma with angiotensin II antagonists
IL206830A0 (en) Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
WO2004103288A3 (en) Method of preventing recurrent miscarriages
WO2005030187A3 (en) Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
WO2001001974A3 (en) Naaladase inhibitors in anxiety and memory disorders
ZA200201819B (en) Preventive and therapeutic agents for eye diseases.
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
YU20104A (en) Methods of treating pulmonary disease
MXPA01008993A (en) Combination treatment for depression and anxiety.
EP1213031A3 (en) Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist
WO2005016327A3 (en) Treatment of sleep disorders with cholinesterase inhibitors
MXPA05013104A (en) Method for the treatment or prevention of lower urinary tract symptoms.
TW200617176A (en) Methods for predicting therapeutic response to agents acting on the growth hormone receptor
WO2000025766A3 (en) Use of nk antagonist for treating gastric asthma
EP1099446A3 (en) Combination treatment for depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10258259

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001932539

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001932539

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP